182 related articles for article (PubMed ID: 19816027)
21. First-trimester screening for trisomy 21 in twin pregnancy: does the addition of biochemistry make an improvement?
Goncé A; Borrell A; Fortuny A; Casals E; Martínez MA; Mercadé I; Cararach V; Vanrell JA
Prenat Diagn; 2005 Dec; 25(12):1156-61. PubMed ID: 16231401
[TBL] [Abstract][Full Text] [Related]
22. [Prenatal diagnosis].
Miny P; Tercanli S; Gänshirt D; Holzgreve W
Ther Umsch; 1995 Dec; 52(12):792-800. PubMed ID: 8539649
[TBL] [Abstract][Full Text] [Related]
23. [How to improve the screening and diagnosis of fetal aneuploidy?].
Ville Y
Bull Acad Natl Med; 2005 Nov; 189(8):1773-84; discussion 1784-7. PubMed ID: 16737102
[TBL] [Abstract][Full Text] [Related]
24. Ultrasonographic markers for chromosomal abnormalities in women with negative nuchal translucency and second trimester maternal serum biochemistry.
Verdin SM; Whitlow BJ; Lazanakis M; Kadir RA; Chatzipapas I; Economides DL
Ultrasound Obstet Gynecol; 2000 Oct; 16(5):402-6. PubMed ID: 11169322
[TBL] [Abstract][Full Text] [Related]
25. Multivariate analysis identifies the estradiol level at ovulation triggering as an independent predictor of the first trimester pregnancy-associated plasma protein-A level in IVF/ICSI pregnancies.
Giorgetti C; Vanden Meerschaut F; De Roo C; Saunier O; Quarello E; Hairion D; Penaranda G; Chabert-Orsini V; De Sutter P
Hum Reprod; 2013 Oct; 28(10):2636-42. PubMed ID: 23887070
[TBL] [Abstract][Full Text] [Related]
26. Screening at 11-13+6 weeks' gestation.
Sonek JD; Nicolaides KH; Janku P
Ceska Gynekol; 2012 Apr; 77(2):92-104. PubMed ID: 22702065
[TBL] [Abstract][Full Text] [Related]
27. [Ultrasound screening for Down syndrome and other chromosomal abnormalities by fetal nuchal translucency measurement between 11-14 weeks of gestation].
Dimitrova V; Markov D; Chernev T; Karag'ozova Zh; Mazneĭkova V; Andonova S; Vŭzharova R
Akush Ginekol (Sofiia); 2005; 44(1):32-7. PubMed ID: 15853009
[TBL] [Abstract][Full Text] [Related]
28. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population.
Schuchter K; Hafner E; Stangl G; Ogris E; Philipp K
Ultrasound Obstet Gynecol; 2001 Jul; 18(1):23-5. PubMed ID: 11489220
[TBL] [Abstract][Full Text] [Related]
29. Trisomies and other chromosome abnormalities detected after positive sonographic findings.
Beke A; Papp C; Tóth-Pál E; Mezei G; Joó JG; Csaba A; Papp Z
J Reprod Med; 2005 Sep; 50(9):675-91. PubMed ID: 16363756
[TBL] [Abstract][Full Text] [Related]
30. Comparison of combined, stepwise sequential, contingent, and integrated screening in 7292 high-risk pregnant women.
Guanciali-Franchi P; Iezzi I; Palka C; Matarrelli B; Morizio E; Calabrese G; Benn P
Prenat Diagn; 2011 Nov; 31(11):1077-81. PubMed ID: 21800336
[TBL] [Abstract][Full Text] [Related]
31. Fetal chromosomal abnormalities: antenatal screening and diagnosis.
Anderson CL; Brown CE
Am Fam Physician; 2009 Jan; 79(2):117-23. PubMed ID: 19178062
[TBL] [Abstract][Full Text] [Related]
32. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM
Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
[TBL] [Abstract][Full Text] [Related]
33. Influence of gravidity and foetal gender on the value of screening variables in the first trimester of pregnancy.
Illescas T; Fernández C; Ortega D; de la Puente M; Coronado P; Montalvo J
Eur J Obstet Gynecol Reprod Biol; 2013 Mar; 167(1):14-7. PubMed ID: 23178003
[TBL] [Abstract][Full Text] [Related]
34. [Prenatal screening for anueploidies in the first trimester: Audit to a Fetal Medicine Centre with specialized Laboratory in Mexico].
Oviedo-Cruz H; Hernández-Paredez J; Ruíz-Ramírez AV
Ginecol Obstet Mex; 2015 May; 83(5):259-76. PubMed ID: 26233972
[TBL] [Abstract][Full Text] [Related]
35. First-trimester nuchal translucency screening for fetal aneuploidy.
Sherer DM; Manning FA
Am J Perinatol; 1999; 16(3):103-20. PubMed ID: 10438192
[TBL] [Abstract][Full Text] [Related]
36. National decline in invasive prenatal diagnostic procedures in association with uptake of combined first trimester and cell-free DNA aneuploidy screening.
Robson SJ; Hui L
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):507-10. PubMed ID: 26259499
[TBL] [Abstract][Full Text] [Related]
37. The impact of inherited thrombophilia on first trimester combined aneuploidy screening test parameters.
Karsli MF; Baser E; Seckin KD; Yeral Mİ; Togrul C; Ugur M
J Matern Fetal Neonatal Med; 2014 Mar; 27(4):346-9. PubMed ID: 23795618
[TBL] [Abstract][Full Text] [Related]
38. Uptake of prenatal screening for chromosomal anomalies: impact of test results in a previous pregnancy.
Spencer K
Prenat Diagn; 2002 Dec; 22(13):1229-32. PubMed ID: 12478639
[TBL] [Abstract][Full Text] [Related]
39. First-trimester screening for aneuploidy with fetal nuchal translucency in a United States population.
Chasen ST; Sharma G; Kalish RB; Chervenak FA
Ultrasound Obstet Gynecol; 2003 Aug; 22(2):149-51. PubMed ID: 12905508
[TBL] [Abstract][Full Text] [Related]
40. Nuchal translucency as a method of first-trimester screening for aneuploidy.
Naidoo P; Erasmus I; Jeebodh J; Nicolaou E; van Gelderen CJ
S Afr Med J; 2008 Apr; 98(4):295-9. PubMed ID: 18637640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
